Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NanoAb COVID-19
- Development stage
- Unknown
- Lead developer
- Scinai Immunotherapeutics
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Inhalation
01
Overview
NanoAb COVID-19 is an inhaled, alpaca-derived VHH-antibody (nanobody) therapy developed by BiondVax Pharmaceuticals in collaboration with the Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Göttingen. Designed for both the prophylactic and therapeutic treatment of COVID-19, these nanosized antibodies target the SARS-CoV-2 virus with significantly higher affinity than conventional monoclonal antibodies, neutralizing variants ranging from the original Wuhan strain to Omicron sub-variants (BA.4/5 and BQ.1) at concentrations up to 100 times lower. The therapy is uniquely hyper-thermostable, maintaining structural integrity at temperatures up to 95°C, and is administered via inhalation to deliver the biologic directly to the respiratory tract, the primary site of infection.
- Other names
- BiondVax NanoAbinhaled nanosized antibody therapy
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on NanoAb COVID-19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NanoAb COVID-19.